Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate Powder Palbociclib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Palbociclib
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Palbociclib
• Name: Palbociclib Powder
• Appearance: off-White or White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anti-Cancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 571190-30-2
• Mf: C24h29n7o2
• MW: 447.53300
• Density: 1.313G/Cm3
• Melting Point: 200 C
• Boiling Point: 711.5 C at 760 Mmhg
• Transport Package: Negotiable
• Specification: Negotiable
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

Raw Material Powder CAS 571190-30-2 Palbociclib Palbociclib Intermediate powder Palbociclib

Product Description

 

Product Details

 

Product Name	Palbociclib
CAS No.	571190-30-2
MF	C24H29N7O2
MW	447.53300
Appearance and shape	Off-white or white powder

Palbociclib is a cyclin-dependent kinase (CDK) 4 and CDK6 inhibitor approved by the FDA to treat hormone receptor-positive (HR+) human epidural 2-negative (HER2-) metastatic breast cancer.   It is used in combination with letrazole as the first-line hormonal-based therapy in postmenopausal women, or with fu lvestrant in women with disease progression following hormonal therapy.   Palbociclib was discovered at Warner- Lambert and developed by Pfizer after their merger.   Pfizer is also studying the effectiveness of palbociclib in a variety of other cancers at various stages in the clinic.

Application & Function

 

 

Palbociclib (codenamed PD-0332991) is a drug for the treatment of ER-positive and HER2-negative breast cancer developed.  It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.

Specification